ArticleDermatology and therapy2024

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).

Mario Valenti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.